The Week in Review: Fosun Pharma Plans Large Hong Kong IPO

Shanghai Fosun Pharma’s on-again/off-again Hong Kong IPO is now scheduled to take place early this year, according to reports; Shanghai Pharma will buy Changzhou Kony Pharm to boost its portfolio of APIs for antivirals and cardiovascular drugs; Shanghai Pharma will also set up a Beijing headquarters for North China with $80 million of initial capital; Shanghai Biochip (ShanghaiBio) signed an MOU with GeneNews Limited to form a molecular diagnostics collaboration; Changchun BCHT Biotechnology obtained an exclusive license for an attenuated flu vaccine technology from BioDiem; Takeda Pharma established a new China division, Takeda Shanghai Development Center, which will run the company’s clinical development projects in Asia; and Nanjing Pharma’s declining fortunes are rumored to have made the company a takeover target. More details….. Stock Symbols: (SHA: 600196) (SHA: 601607; HK: 02607) (TO: 4502) (SHA: 600713) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});